What's happening
This bill creates new safety and quality requirements for insurer-designated pharmacies distributing patient-specific medications to healthcare providers for administration.
Why it matters
Limits "brown bagging" of medications. The bill prohibits insurers and health plans from requiring patients to pick up medications at insurer-designated pharmacies and then transport them to a provider's office for administration. This addresses risks of improper handling, loss of drug efficacy, and patient confusion.
Raises standards for drug distribution to providers. When insurers or plans do require drugs to be sent directly to provider offices, there must be formal agreements ensuring safe receipt, transfer, storage, and handling—including cold chain management, delivery in ready-to-administer form, and documentation of the medication’s supply chain pedigree.
Protects patient safety through exceptions and restrictions. Providers can invoke an expedited exception process if they certify that pharmacy-supplied medications are unsafe for a specific patient. Additionally, the bill bans insurer-mandated distribution for drugs that require sterile compounding or patient-specific dosing based on same-day tests, reducing the risk of medication errors.
Aims for fair payments and less administrative burden. The bill requires insurers to offer “site neutral” payments to providers, covering costs of intake, storage, and disposal of these medications and preventing financial disincentives for provider-administered drugs, potentially improving access and provider participation.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Health insurers and health care plans
The bill would require provider agreements with safety safeguards before mandating delivery from designated pharmacies and prohibit requiring home infusion or infusion outside a patient's provider office or clinic.
Physicians, hospitals and clinics
The bill would require payments covering medication intake, storage and disposal costs and bar mandated designated-pharmacy delivery for drugs requiring provider sterile compounding or dosing based on same-day test results.
Insurer-designated pharmacies
Required delivery arrangements would include same-day delivery, round-the-clock pharmacist or nurse access, temperature controls, national accreditation and ready-to-administer doses.
Patients receiving provider-administered medications
The bill would prohibit insurers from allowing or requiring pharmacy dispensing intended for patients to transport drugs to providers and require expedited exceptions when providers certify designated-pharmacy supply is unsafe.
Headline styles
Protect Patients' Medication Safety
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Protect Patients’ Medication Safety
In Senate Committee · Insurance · Sponsor Neil D. Breslin
Full text
4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
2163
2023-2024 Regular Sessions
IN ASSEMBLY
January 23, 2023
Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law and the public health law, in relation to establishing patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurerdesignated pharmacy
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 3217-b of the insurance law is amended by adding a new subsection (p) to read as follows:
(p) (1) No insurer subject to this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that such patient will transport such medication to a physician's office, hospital or clinic for administration.
(2) An insurer subject to this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(3) An insurer subject to this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(A) provide at least ninety days' notice to providers and insurers prior to the implementation of such a requirement;
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05796-01-3
(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;
(C) provide same day delivery of medications;
(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;
(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(4) No insurer subject to this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 2. Section 4325 of the insurance law is amended by adding a new subsection (p) to read as follows:
(p) (1) No corporation organized under this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.
(2) A corporation organized under this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(3) A corporation organized under this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(A) provide at least ninety days' notice to providers and insureds prior to the implementation of such a requirement;
(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;
(C) provide same day delivery of medications;
(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;
(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(4) No corporation organized under this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 3. Section 4406-c of the public health law is amended by adding a new subdivision 13 to read as follows:
13. (a) No health care plan shall by contract or written policy or written procedure allow or require a plan-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.
(b) A health care plan may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(c) A health care plan, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(i) provide at least ninety days' notice to providers and enrollees prior to the implementation of such a requirement;
(ii) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from a plan-designated pharmacy;
(iii) provide same day delivery of medications;
(iv) make available on-call access to a pharmacist or nurse twentyfour hours per day, seven days per week;
(v) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
(vi) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(vii) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(viii) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(ix) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(x) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(d) No health care plan shall by contract, written policy or written procedure require (i) a medication requiring sterile compounding by a provider, or (ii) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from a plan-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.